Royalty Pharma plc
60.59USD
+0.0000 (+0.00%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $1.18▲ | $1.13 | 4 | 1 |
| Next quarter | $1.55▲ | $1.5 | 4 | 1 |
| Current year | $5.34▲ | $5.12 | 6 | 0 |
| Next year | $5.73▲ | $5.61 | 5 | 0 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $1.27 | $1.32 | +0.05 (+3.9%) |
| 2026-03-31 | $1.18 | $1.3 | +0.11 (+9.4%) |
| 2025-12-31 | $1.33 | $1.47 | +0.13 (+10.0%) |
| 2025-09-30 | $1.04 | $1.17 | +0.13 (+12.5%) |
48 ratings from 11 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| TD Cowen | Maintained | Buy | $65 $68 | Sep 8, 2026 |
| JP Morgan | Maintained | Overweight | $58 $62 | Aug 7, 2026 |
| TD Cowen | Maintained | Buy | $50 $65 | Jul 13, 2026 |
| Citigroup | Maintained | Buy | $50 $66 | May 7, 2026 |
| JP Morgan | Maintained | Overweight | $50 $58 | May 7, 2026 |
| UBS | Maintained | Buy | $51 $57 | Apr 21, 2026 |
| Morgan Stanley | Maintained | Overweight | $61 $63 | Apr 10, 2026 |
| UBS | Upgraded from Neutral | Buy | $38 $49 | Jan 30, 2026 |
| Citigroup | Maintained | Buy | $48 $50 | Jan 27, 2026 |
| TD Cowen | Maintained | Buy | $42 $45 | Dec 11, 2025 |
| Morgan Stanley | Maintained | Overweight | $55 $54 | Oct 10, 2025 |
| Goldman Sachs | Initiated | Buy | $42 | Sep 30, 2025 |
| Citigroup | Maintained | Buy | $40 $42 | Jul 22, 2025 |
| Morgan Stanley | Maintained | Overweight | $51 $54 | Jul 10, 2025 |
| Citigroup | Maintained | Buy | $60 $40 | Oct 25, 2024 |
| Goldman Sachs | Maintained | Buy | $50 $51 | Aug 14, 2024 |
| Morgan Stanley | Maintained | Overweight | $48 $51 | Jul 11, 2024 |
| UBS | Downgraded from Buy | Neutral | $28 | Jun 3, 2024 |
| B of A Securities | Maintained | Buy | $40 $38 | Apr 12, 2024 |
| JP Morgan | Maintained | Overweight | $45 $42 | Feb 20, 2024 |
| Goldman Sachs | Maintained | Buy | $56 $50 | Feb 20, 2024 |
| Morgan Stanley | Maintained | Overweight | $54 $57 | Nov 9, 2023 |
| Morgan Stanley | Maintained | Overweight | $53 $54 | Oct 11, 2023 |
| Morgan Stanley | Maintained | Overweight | $52 $53 | Aug 9, 2023 |
| Morgan Stanley | Reiterated | Overweight | $52 | Jul 11, 2023 |
98 filings from 15 insiders · 19 buy / 13 sell over 6m
Officers and directors of RPRX, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| HITE CHRISTOPHEROfficer | Gift | 16.8k | — | — | Aug 19, 2026 |
| HITE CHRISTOPHEROfficer | Sellindirect | 100.0k | $59.97 | $6.00M | Aug 18, 2026 |
| COYNE TERRANCE PChief Financial Officer | Sellindirect | 11.0k | $58.59 | $646k | Aug 13, 2026 |
| HITE CHRISTOPHEROfficer | Grantindirect | 11.0k | — | — | Aug 5, 2026 |
| COYNE TERRANCE PChief Financial Officer | Grantindirect | 11.0k | — | — | Aug 5, 2026 |
| URIST MARSHALL J.Officer | Grant | 8.3k | — | — | Aug 5, 2026 |
| LEGORRETA PABLO GChief Executive Officer | Grant | 65.2k | — | — | Aug 5, 2026 |
| URIST MARSHALL J.Officer | Sell | 9.1k | $55.88 | $508k | Jul 1, 2026 |
| HITE CHRISTOPHEROfficer | Sell | 130.0k | $56.44 | $7.35M | Jun 30, 2026 |
| BASSLER BONNIE LDirector | Grant | 689 | $54.40 | $37k | Jun 30, 2026 |
| URIST MARSHALL J.Officer | Sell | 9.1k | $55.18 | $502k | Jun 24, 2026 |
| HITE CHRISTOPHEROfficer | Sellindirect | 150.0k | $54.11 | $8.16M | Jun 23, 2026 |
| ENGELBERT CATHERINE M.Director | Grant | 4.5k | — | — | Jun 5, 2026 |
| NORDEN GREGORYDirector | Grant | 4.5k | — | — | Jun 5, 2026 |
| BASSLER BONNIE LDirector | Grant | 4.5k | — | — | Jun 5, 2026 |
| CORIC VLADIMIRDirector | Grant | 4.5k | — | — | Jun 5, 2026 |
| HO CAROLEDirector | Grant | 4.5k | — | — | Jun 5, 2026 |
| LOVE TED WENDELLDirector | Grant | 4.5k | — | — | Jun 5, 2026 |
| HODGSON DAVID CDirector | Grant | 4.5k | — | — | Jun 5, 2026 |
| WEATHERMAN ELIZABETH HDirector | Grant | 4.5k | — | — | Jun 5, 2026 |
No analyst notes on RPRX yet.
Analyst Ratings
8 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 2 | 5 | 1 | 0 | 0 | Buy1.88 |
| 1 mo ago | 2 | 5 | 1 | 0 | 0 | Buy1.88 |
| 2 mo ago | 2 | 6 | 2 | 0 | 0 | Buy2.00 |
| 3 mo ago | 2 | 6 | 2 | 0 | 0 | Buy2.00 |